Stockscreener 앱 받기
76.49
1.34%
1.01
전일 마감가:
$75.48
열려 있는:
$75.5
하루 거래량:
1.22M
Relative Volume:
0.56
시가총액:
$14.74B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-31.74
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-0.05%
1개월 성능:
+6.22%
6개월 성능:
+77.14%
1년 성능:
+178.75%
1일 변동 폭
$74.99
$77.28
1주일 범위
$74.47
$77.48
52주 변동 폭
$27.53
$78.44
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
76.49 | 14.55B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 개시 | Bernstein | Outperform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
Moody Aldrich Partners LLC Has $3.72 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Behavioral Patterns of BBIO and Institutional Flows - Stock Traders Daily
Corient Private Wealth LLC Acquires New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Aug Chart Watch: How BridgeBio Pharma Inc stock compares to industry benchmarksWeekly Trend Summary & Precise Trade Entry Recommendations - moha.gov.vn
BridgeBio Pharma Earnings Notes - Trefis
BridgeBio Has More Room To Run (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month HighHere's Why - MarketBeat
BridgeBio Pharma stock hits all-time high at $77.32 By Investing.com - Investing.com Nigeria
BridgeBio Pharma stock hits all-time high at $77.32 - Investing.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assenagon Asset Management S.A. Trims Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Why global investors buy BridgeBio Pharma Inc. (2CL) stockJuly 2025 Fed Impact & Low Risk Entry Point Guides - Улправда
Will BridgeBio Pharma Inc. stock benefit from commodity pricesTrade Entry Report & Real-Time Sentiment Analysis - Улправда
Why BridgeBio Pharma Inc. stock could rally in 20252025 Year in Review & Safe Investment Capital Preservation Plans - ulpravda.ru
First Week of August 2026 Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
What hedge fund activity signals for BridgeBio Pharma Inc. stock2025 Big Picture & Reliable Entry Point Trade Alerts - Улправда
Gains Recap: Why BridgeBio Pharma Inc. stock could rally in 2025Analyst Upgrade & Weekly Top Stock Performers List - Улправда
Will BridgeBio Pharma Inc. stock maintain growth story2025 Market Trends & Low Risk Growth Stock Ideas - Улправда
BridgeBio Pharma Sees Unusually Large Options Volume (NASDAQ:BBIO) - MarketBeat
Layoff Watch: What hedge fund activity signals for BridgeBio Pharma Inc. stockJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Path To Profitability - 富途牛牛
Hypoparathyroidism Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing - marketscreener.com
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 30,011 Shares - MarketBeat
Pres Trimarchi Acquires 11,174 Of Bridgebio Pharma Inc [BBIO] - TradingView — Track All Markets
BridgeBio Pharma (BBIO) CEO discloses RSU vesting and stock sales - Stock Titan
Officer Apuli Acquires 1,941 Of Bridgebio Pharma Inc [BBIO] - TradingView — Track All Markets
BridgeBio Pharma (NASDAQ: BBIO) CFO notes 13,826 shares withheld for taxes - Stock Titan
BridgeBio Pharma (BBIO) CAO discloses RSU tax share withholding - Stock Titan
BridgeBio Pharma (BBIO) Receives Maintained Rating with Raised P - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighTime to Buy? - MarketBeat
Is the Market Bullish or Bearish on BridgeBio Pharma Inc? - Benzinga
Castleark Management LLC Cuts Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Gilder Gagnon Howe & Co. LLC Boosts Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Eventide Asset Management LLC Decreases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha
BridgeBio Pharma stock hits all-time high at 75.13 USD - Investing.com
BridgeBio Pharma stock hits all-time high at 75.13 USD By Investing.com - Investing.com Australia
BridgeBio Pharma (BBIO) Valuation After Attruby-Driven Earnings Beat and Renewed Analyst Support - Yahoo Finance
What Recent Clinical Wins Mean For BridgeBio Pharma’s Evolving Growth Story - Yahoo Finance
Frontier Capital Management Co. LLC Sells 233,538 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bernstein initiates BridgeBio Pharma stock coverage with Outperform rating By Investing.com - Investing.com Canada
Check out BridgeBio Pharma's stock price (1BBIO-IT) in real time - CNBC
Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target - marketscreener.com
This Option Care Health Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - Benzinga
HighVista Strategies LLC Increases Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bernstein Initiates Coverage of BridgeBio Pharma (BBIO) with Outperform Recommendation - Nasdaq
BBIO Gets "Outperform" Rating as Bernstein Initiates Coverage | - GuruFocus
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
자본화:
|
볼륨(24시간):